Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P00973: Variant p.Cys109Tyr

2'-5'-oligoadenylate synthase 1
Gene: OAS1
Feedback?
Variant information Variant position: help 109 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Cysteine (C) to Tyrosine (Y) at position 109 (C109Y, p.Cys109Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In IMD100; results in increased 2'-5'-oligoadenylate synthetase activity leading to increased RNase L-mediated cellular RNA degradation, translational arrest and apoptosis. Any additional useful information about the variant.


Sequence information Variant position: help 109 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 400 The length of the canonical sequence.
Location on the sequence: help QDQLNRRGEFIQEIRRQLEA C QRERAFSVKFEVQAPRWGNP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 400 2'-5'-oligoadenylate synthase 1
Helix 88 – 111



Literature citations
Heterozygous Mutations in OAS1 Cause Infantile-Onset Pulmonary Alveolar Proteinosis with Hypogammaglobulinemia.
Cho K.; Yamada M.; Agematsu K.; Kanegane H.; Miyake N.; Ueki M.; Akimoto T.; Kobayashi N.; Ikemoto S.; Tanino M.; Fujita A.; Hayasaka I.; Miyamoto S.; Tanaka-Kubota M.; Nakata K.; Shiina M.; Ogata K.; Minakami H.; Matsumoto N.; Ariga T.;
Am. J. Hum. Genet. 102:480-486(2018)
Cited for: VARIANTS IMD100 VAL-76; TYR-109 AND VAL-198; INVOLVEMENT IN IMD100; Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.
Magg T.; Okano T.; Koenig L.M.; Boehmer D.F.R.; Schwartz S.L.; Inoue K.; Heimall J.; Licciardi F.; Ley-Zaporozhan J.; Ferdman R.M.; Caballero-Oteyza A.; Park E.N.; Calderon B.M.; Dey D.; Kanegane H.; Cho K.; Montin D.; Reiter K.; Griese M.; Albert M.H.; Rohlfs M.; Gray P.; Walz C.; Conn G.L.; Sullivan K.E.; Klein C.; Morio T.; Hauck F.;
Sci. Immunol. 6:0-0(2021)
Cited for: VARIANTS IMD100 VAL-76; TYR-109; GLY-121 AND VAL-198; CHARACTERIZATION OF VARIANTS IMD100 VAL-76; TYR-109; GLY-121 AND VAL-198; INVOLVEMENT IN IMD100; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.